Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) patients frequently develop treatment resistance to cetuximab, a monoclonal antibody against EGFR, as well as radiotherapy. Here we addressed extracellular signal-regulated kinase 1/2 (ERK1/2) regulation by cetuximab or fractionated irradiati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Rong, Chao, Muller, Marie F., Xiang, Fang, Jensen, Alexandra, Weichert, Wilko, Major, Gerald, Plinkert, Peter K., Hess, Jochen, Affolter, Annette
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7374086/
https://ncbi.nlm.nih.gov/pubmed/32424150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-020-0892-9
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky